Compare IRIX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | IGC |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 28.5M |
| IPO Year | 1996 | 2005 |
| Metric | IRIX | IGC |
|---|---|---|
| Price | $1.40 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 58.1K | ★ 350.9K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.47 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,593,000.00 | $1,271,000.00 |
| Revenue This Year | $9.61 | $3.54 |
| Revenue Next Year | $8.12 | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.24 |
| 52 Week High | $1.65 | $0.50 |
| Indicator | IRIX | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 55.49 |
| Support Level | $1.33 | N/A |
| Resistance Level | $1.51 | $0.32 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 41.67 | 67.14 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.